| 摘要 |
The present invention provides for a novel peptidic antagonist for the bradykinin B1 (BKB<SUB>1</SUB>) receptor having very good to excellent affinities and selectivity for the BKB<SUB>1 </SUB>receptor, in vitro and in vivo increase resistance to enzymatic degradation, superior pharmacokinetic properties, capability to significantly reduce microvascular leakage observed alongside diabetic-induced increase in vascular permeability, capability to significantly reduced the state of hyperalgesia alongside diabetes, capability to significantly reduce the infiltration of pro-inflammatory cells and general state of inflammation alongside allergic asthma.
|
